Effects of Obesity on Lipid-Lowering, Anti-Inflammatory, and Antiatherosclerotic Benefits of Atorvastatin or Pravastatin in Patients With Coronary Artery Disease (from the REVERSAL Study)

American Journal of Cardiology

Volumn 97, Issue 11, 2006, Pages 1553-1557

  Nicholls, Stephen J ^a   Tuzcu, E Murat ^a   Sipahi, Ilke ^a   Schoenhagen, Paul ^a   Hazen, Stanley L ^a   Ntanios, Fady ^b   Wun, Chuan Chuan ^b   Nissen, Steven E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; INTRAVASCULAR ULTRASOUND; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CORONARY DISEASE; CORONARY VESSELS; DISEASE PROGRESSION; ENDOSONOGRAPHY; FEMALE; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; OBESITY; PRAVASTATIN; PYRROLES; RISK FACTORS;

EID: 33646686191     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.12.042     Document Type: Article

References (12)

1. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. a randomized controlled trial. JAMA 291 (2004) 1071-1080
2. Grundy S.M. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol 90 suppl (2002) 11i-21i
3. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O'Shaughnessy C., and Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
4. Ferroni P., Basili S., Falco A., and Davi G. Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep 6 (2004) 424-431
5. Toni R., Malaguti A., Castorina S., Roti E., and Lechan R.M. New paradigms in neuroendocrinology. relationships between obesity, systemic inflammation and the neuroendocrine system. J Endocrinol Invest 27 (2004) 182-186
6. Cassidy A.E., Bielak L.F., Zhou Y., Sheedy II P.F., Turner S.T., Breen J.F., Araoz P.A., Kullo I.J., Lin X., and Peyser P.A. Progression of subclinical coronary atherosclerosis. does obesity make a difference?. Circulation 111 (2005) 1877-1882
7. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
8. Schectman G., and Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies. implications for treatment. Ann Intern Med 125 (1996) 990-1000
9. Stoll L.L., McCormick M.L., Denning G.M., and Weintraub N.L. Antioxidant effects of statins. Drugs Today (Barc) 40 (2004) 975-990
10. Inoue I., Itoh F., Aoyagi S., Tazawa S., Kusama H., Akahane M., Mastunaga T., Hayashi K., Awata T., Komoda T., and Katayama S. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 290 (2002) 131-139
11. Shishehbor M.H., Brennan M.L., Aviles R.J., Fu X., Penn M.S., Sprecher D.L., and Hazen S.L. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426-431
12. Shishehbor M.H., Aviles R.J., Brennan M.L., Fu X., Goormastic M., Pearce G.L., Gokce N., Keaney Jr. J.F., Penn M.S., Sprecher D.L., et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289 (2003) 1675-1680